Arlene Weintraub

Arlene Weintraub
Arlene Weintraub
Contributing Writer

Arlene Weintraub has over 15 years of experience writing about health care, pharmaceuticals and biotechnology. Her freelance pieces have been published in the New York Times, US News & World Report, Technology Review, Scientific American, USA Today,, FierceMarkets and other media outlets. She was previously a senior health writer for BusinessWeek, covering both the science and business of health. She also worked as an editor for, covering the biotech industry, as well as technology, life sciences and clean technology companies. She has won awards from the New York Press Club, the Association of Health Care Journalists, the Foundation for Biomedical Research, and the American Society of Business Publication Editors. Her book about the antiaging industry, Selling the Fountain of Youth, was published by Basic Books in 2010.

Stories by Arlene Weintraub

Two proteins could be key to regenerating bone

Several potential therapies for regenerating bone lost to disease or trauma are under investigation, from embryonic stem cells to novel chemical compounds. Now scientists at the University of Wisconsin-Madison are adding something new to the mix: two proteins in bone marrow that they believe regulate master cells in the bone-making process.

How human-pig chimeras could boost regenerative medicine

Scientists at the Salk Institute generated plenty of buzz on January 26 when they announced they had successfully grown embryos containing cells from both pigs and humans. Despite challenges, they are certain their invention could prove valuable for a range of scientific pursuits, from drug development to regenerative medicine.
red blood cells

Harnessing light and red blood cells to improve drug delivery

Scientists at the University of North Carolina at Chapel Hill have been working on an innovative way to target drug delivery only to the tissues of the body that need to be treated, using a combination of red blood cells and light. And the technique is so promising they’re creating a company to further develop it.